Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
OSB GROUP PLC - Transaction in Own Shares
-
Transaction in Own Shares
-
SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
-
Initial admission to the Official List
-
AI Agents to Power 1,000% More Customer Interactions for Enterprises Globally by 2027
-
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
-
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
-
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
-
Sampo plc’s share buybacks 5 December 2025
-
L’ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
-
Start of Day Message
-
BNP PARIBAS : BNP PARIBAS GROUP SELLS ITS STAKE IN AG INSURANCE AND FORMALISES LONG TERM PARTNERSHIP WITH AGEAS
-
Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas
-
YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE
-
NOTICE TO DISREGARD -- ICARO Media Group
-
SED Initta and Intel Deepen Strategic Partnership to Accelerate AI-Driven Retail Transformation
-
HVAC Expert Ben Fleck of Gretna Advises Homeowners to Change Air Filters Regularly in HelloNation
-
Pest Control Expert Steven Moore of Port Washington Shares The Top 4 Household Pests for HelloNation
-
Collision Repair Expert Andy Spence of Jackson, TN, Explains Why Certified Collision Repair Matters for HelloNation
-
Retail Expert Melissa Skelton Shares Insights on Custom vs. Commercial Easter Gifts in New HelloNation Feature
-
Laser Hair Removal Expert Dr. Terese Thomas, MD Explains Sublative Radiofrequency vs Facial in HelloNation
-
Marine Transport Expert Jon Arrigoni of Arrigoni Marine Movers Warns Boat Owners About Insurance Gaps in HelloNation
-
Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer
-
HeroFlow Announces Expansion of Access to “The AI Employee,” the 24/7 Virtual Receptionist That Never Calls In Sick
-
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA Fac
-
The Ohio State University’s Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal
-
OPay Appoints Former Citigroup Managing Director James Perry as CFO
-
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
-
Skyline Digital Marketing Introduces Proprietary Skyline Methodology to Strengthen Data-Driven Business Growth
-
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
-
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
-
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Am
-
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
-
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
-
Drilling hits wide zone of mineralisation in new area well outside resource
-
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
-
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and
-
Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025
-
Rally House Breaks Company Online Sales Record After Electric Sports Weekend
-
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Mu
-
Nayax Considering an Offering of Notes and Warrants in Israel
-
Real Estate Expert Kerry Ramage of Melbourne, FL, Breaks Down Home Sale Strategy for HelloNation
-
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
-
Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting
-
Mutuum Finance (MUTM) Approaches 100% Presale Sellout Amid Ongoing Halborn Security Review
-
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodg
